Effect of captopril on norepinephrine vascular contractility

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Renal Physiology

Background:

• Norepinephrine (NE) is a potent vasoconstrictor.
• Captopril is an angiotensin-converting enzyme (ACE) inhibitor.
• The role of the renin-angiotensin system (RAS) in mediating vascular responses to NE requires clarification.

Purpose of the Study:

• To investigate the effect of captopril on norepinephrine-induced vasoconstriction.
• To determine if captopril's effects are mediated by alpha-adrenergic receptor antagonism or RAS inhibition.

Main Methods:

• Isolated aortic rings and perfused mesenteric arteries from Wistar rats were used.
• Experiments were conducted in pithed Wistar rats.
• Vascular responses to norepinephrine were measured before and after captopril administration.
• Angiotensin II infusion and nephrectomy were employed to probe the role of the RAS.

Main Results:

• Captopril did not alter NE-induced vasoconstriction in isolated vessels.
• In pithed rats, captopril significantly attenuated NE-induced increases in diastolic blood pressure.
• The inhibitory effect of captopril on NE responses was abolished by angiotensin II infusion or nephrectomy.

Conclusions:

• Captopril's attenuation of norepinephrine's pressor effects in vivo is mediated by inhibition of the renin-angiotensin system.
• Captopril does not act as an alpha-adrenergic antagonist.
• These findings highlight the interaction between the sympathetic nervous system and the RAS in regulating blood pressure.